▲ +81.80% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for TCR2 Therapeutics in the last 3 months. The average price target is $43.29, with a high forecast of $56.00 and a low forecast of $32.00. The average price target represents a 81.80% upside from the last price of $23.81.
The current consensus among 8 investment analysts is to buy stock in TCR2 Therapeutics. This Buy consensus rating has held steady for over two years.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.